Negar Jafari
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Negar Jafari has a total of 70 co-authors. Here are the top co-authors by number of shared publications:
- Mohammadreza Saberiyan
Student Research Committee, Hormozgan University of Medical Sciences, Bandar Abbas, Iran
4 shared publications - Reza Faramarzzadeh
Department of Cardiology, Seyed-al-shohada Cardiology Hospital, Urmia University of Medical Science, Urmia, Iran
4 shared publications - Venus Shahabi Rabori
Department of Cardiology, School of Medicine, Urmia University of Medical Sciences, Urmia, Iran
4 shared publications - Ali Zolfi Gol
Department of Pediatric Diseases, Faculty of Medicine, Urmia University of Medical Sciences, Urmia, Iran
3 shared publications - Saeid Heidari-Soureshjani
Clinical Biochemistry Research Center, Basic Health Sciences Institute, Shahrekord University of Medical Sciences, Shahrekord, Iran
3 shared publications - Shahab Masoumi
Cardiovascular Fellowship, Cardiovascular Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
3 shared publications
Latest Publications
- 1 November 2025
- Published byĀ Bentham Science Publishers Ltd.Ā inĀ The Natural Products Journal
- Vol.Ā 15 Ā (8) , 1-17
The Biological Effects of Soy Isoflavones against Myocardial Ischemia-reperfusion Injuries: A Systematic Review
Background: Myocardial Ischemia-Reperfusion Injury (MIRI) is associated with adverse cardiovascular outcomes that lead to the death of ischemic cardiomyocytes and, finally, dysfunction of cardiac tissue. Objectives: This systematic review aims to comprehensively investigate and systematically review the existing literature on the effects of soy isoflavones and their underlying mechanisms in mitigating MIRI injuries. Methods: A systematic search was conducted in high-coverage scientific databases, including Web of Science, MEDLINE/PubMed, Scopus, Embase, and Cochrane Library. On 6th December, 2023, an extensive literature search was done using predefined search terms (According to MeSH terms) and inclusion criteria. Any studies that investigated the effects of soy isoflavones on MIRI injuries were included. Search strategy, screening of the publications, and data extraction were performed following PRISMA guidelines 2020. Results: Diverse mechanisms underlying the cardioprotective effects of soy isoflavones against MIRI include antioxidant properties, anti-inflammatory effects, enhanced mitochondrial function, regulation of apoptosis pathways, improving angiogenesis effects, attenuating heart histological changes, modulating factors that affect hemodynamic changes, and reducing Ca+2 overload. Although most studies reported promising effects in reducing the complications of MIRI, a small number of studies also showed no significant effect in this regard. Also, they did not report any specific side effects from consuming isoflavones alone. Conclusion: The findings suggest that soy isoflavones as a complementary therapeutic strategy potentially benefit MIRI outcomes and support their role in cardiovascular health. However, further well-designed clinical trials are warranted to validate these findings and establish their clinical significance in cardiovascular disease management.
- 1 November 2025
- Published byĀ Bentham Science Publishers Ltd.Ā inĀ The Natural Products Journal
- Vol.Ā 15 Ā (8) , 1-17
The Biological Effects of Soy Isoflavones against Myocardial Ischemia-reperfusion Injuries: A Systematic Review
Background: Myocardial Ischemia-Reperfusion Injury (MIRI) is associated with adverse cardiovascular outcomes that lead to the death of ischemic cardiomyocytes and, finally, dysfunction of cardiac tissue. Objectives: This systematic review aims to comprehensively investigate and systematically review the existing literature on the effects of soy isoflavones and their underlying mechanisms in mitigating MIRI injuries. Methods: A systematic search was conducted in high-coverage scientific databases, including Web of Science, MEDLINE/PubMed, Scopus, Embase, and Cochrane Library. On 6th December, 2023, an extensive literature search was done using predefined search terms (According to MeSH terms) and inclusion criteria. Any studies that investigated the effects of soy isoflavones on MIRI injuries were included. Search strategy, screening of the publications, and data extraction were performed following PRISMA guidelines 2020. Results: Diverse mechanisms underlying the cardioprotective effects of soy isoflavones against MIRI include antioxidant properties, anti-inflammatory effects, enhanced mitochondrial function, regulation of apoptosis pathways, improving angiogenesis effects, attenuating heart histological changes, modulating factors that affect hemodynamic changes, and reducing Ca+2 overload. Although most studies reported promising effects in reducing the complications of MIRI, a small number of studies also showed no significant effect in this regard. Also, they did not report any specific side effects from consuming isoflavones alone. Conclusion: The findings suggest that soy isoflavones as a complementary therapeutic strategy potentially benefit MIRI outcomes and support their role in cardiovascular health. However, further well-designed clinical trials are warranted to validate these findings and establish their clinical significance in cardiovascular disease management.
- Open Access
- 27 July 2025
- Published byĀ Salvia Medical Sciences LtdĀ inĀ Galen Medical Journal
- Vol.Ā 14, e3937
Microvascular Dysfunction as a Bridge between Chronic Obstructive Pulmonary Disease and Ischemic Events
Chronic obstructive pulmonary disease (COPD), traditionally viewed as a localized pulmonary disorder, is now recognized as a systemic disease with far-reaching vascular consequences. Among its most concerning comorbidities are ischemic events such as myocardial infarction and stroke, which occur at disproportionately high rates in these patients, even after adjusting for shared risk factors like smoking. This unexpected persistence of risk has driven interest in the underlying mechanisms that might link lung dysfunction to vascular pathology. Emerging evidence suggests that microvascular dysfunction (MVD), characterized by endothelial injury, capillary rarefaction, and impaired vasoreactivity, may serve as a pivotal intermediary in this relationship. Systemic inflammation and oxidative stress, initiated in the lungs, appear to spill over into the circulation, damaging the vascular endothelium and setting the stage for atherosclerosis and ischemic injury. This review synthesizes current findings from molecular, imaging, and epidemiological studies to propose MVD as a central mechanistic bridge between COPD and ischemic events. We also examine therapeutic strategies that target endothelial health and highlight potential opportunities for early intervention. By reframing COPD as a disease with significant vascular implications, this review underscores the need for an integrated clinical approach that goes beyond pulmonary function and addresses systemic vascular health.
- 27 July 2025
- Published byĀ Salvia Medical Sciences LtdĀ inĀ Galen Medical Journal
- Vol.Ā 14, e3937
Open AccessMicrovascular Dysfunction as a Bridge between Chronic Obstructive Pulmonary Disease and Ischemic Events
Chronic obstructive pulmonary disease (COPD), traditionally viewed as a localized pulmonary disorder, is now recognized as a systemic disease with far-reaching vascular consequences. Among its most concerning comorbidities are ischemic events such as myocardial infarction and stroke, which occur at disproportionately high rates in these patients, even after adjusting for shared risk factors like smoking. This unexpected persistence of risk has driven interest in the underlying mechanisms that might link lung dysfunction to vascular pathology. Emerging evidence suggests that microvascular dysfunction (MVD), characterized by endothelial injury, capillary rarefaction, and impaired vasoreactivity, may serve as a pivotal intermediary in this relationship. Systemic inflammation and oxidative stress, initiated in the lungs, appear to spill over into the circulation, damaging the vascular endothelium and setting the stage for atherosclerosis and ischemic injury. This review synthesizes current findings from molecular, imaging, and epidemiological studies to propose MVD as a central mechanistic bridge between COPD and ischemic events. We also examine therapeutic strategies that target endothelial health and highlight potential opportunities for early intervention. By reframing COPD as a disease with significant vascular implications, this review underscores the need for an integrated clinical approach that goes beyond pulmonary function and addresses systemic vascular health.
- Open Access
- 7 July 2025
- Published byĀ WileyĀ inĀ Cancer Reports
- Vol.Ā 8 Ā (7) , e70232
The Expression of lncRNAs EVADR and LUESCC in Colorectal Tumor Tissues and Their Association With the CRC Risk
Background: Colorectal cancer (CRC) is a prevalent form of cancer globally and ranks as the second most common cause of cancerārelated deaths. Long nonācoding RNAs (lncRNAs) are regulatory RNAs that influence gene expression. EVADR and LUESCC are two novel lncRNAs specifically expressed in tumors of glandular origin, such as the colon.Aims: This study aimed to investigate the expression of EVADR and LUESCC in colorectal tumor tissues and evaluate their potential as diagnostic and prognostic biomarkers in CRC.Methods: Fifty cases of colorectal tumor tissues, formalināfixed, paraffināembedded (FFPE) from individuals with sporadic CRC, referred from the Pathology Department of Imam Hossein Hospital in Tehran, Iran, were analyzed. The expression patterns of LUESCC and EVADR lncRNAs in CRC patients were examined.Results: The study reveals upregulation of LUESCC and EVADR lncRNAs in colorectal cancer (CRC) patients compared to normal tissues, with fold changes of 3.52 (p < 0.001) for LUESCC and 3.08 (p < 0.001) for EVADR. ROC curve analysis indicates an area under the curve (AUC) of 0.75 for LUESCC and 0.86 for EVADR, suggesting strong diagnostic potential. Additionally, differential expression analysis shows correlations between lncRNA levels and tumor differentiation grades.Conclusion: This study highlights the potential of LUESCC and EVADR lncRNAs as biomarkers for CRC diagnosis and prognosis. However, limitations include a small sample size that may affect the generalizability of the findings and a lack of functional assays to elucidate their roles in tumor biology. Further research is needed to validate these findings and explore the underlying mechanisms.
- 7 July 2025
- Published byĀ WileyĀ inĀ Cancer Reports
- Vol.Ā 8 Ā (7) , e70232
Open AccessThe Expression of lncRNAs EVADR and LUESCC in Colorectal Tumor Tissues and Their Association With the CRC Risk
Background: Colorectal cancer (CRC) is a prevalent form of cancer globally and ranks as the second most common cause of cancerārelated deaths. Long nonācoding RNAs (lncRNAs) are regulatory RNAs that influence gene expression. EVADR and LUESCC are two novel lncRNAs specifically expressed in tumors of glandular origin, such as the colon.Aims: This study aimed to investigate the expression of EVADR and LUESCC in colorectal tumor tissues and evaluate their potential as diagnostic and prognostic biomarkers in CRC.Methods: Fifty cases of colorectal tumor tissues, formalināfixed, paraffināembedded (FFPE) from individuals with sporadic CRC, referred from the Pathology Department of Imam Hossein Hospital in Tehran, Iran, were analyzed. The expression patterns of LUESCC and EVADR lncRNAs in CRC patients were examined.Results: The study reveals upregulation of LUESCC and EVADR lncRNAs in colorectal cancer (CRC) patients compared to normal tissues, with fold changes of 3.52 (p < 0.001) for LUESCC and 3.08 (p < 0.001) for EVADR. ROC curve analysis indicates an area under the curve (AUC) of 0.75 for LUESCC and 0.86 for EVADR, suggesting strong diagnostic potential. Additionally, differential expression analysis shows correlations between lncRNA levels and tumor differentiation grades.Conclusion: This study highlights the potential of LUESCC and EVADR lncRNAs as biomarkers for CRC diagnosis and prognosis. However, limitations include a small sample size that may affect the generalizability of the findings and a lack of functional assays to elucidate their roles in tumor biology. Further research is needed to validate these findings and explore the underlying mechanisms.
- Open Access
- 1 July 2025
- Published byĀ Springer NatureĀ inĀ Scientific Reports
- Vol.Ā 15 Ā (1) , 1-12
Integrative in Silico and in vitro validation suggest LINC00963 and SNHG15 as candidate biomarkers for coronary artery disease
Despite notable advancements in prevention, medication, and treatment approaches, coronary artery disease (CAD) remains a significant challenge for healthcare systems and the economy. In relation to CAD, long non-coding RNAs (lncRNAs) can impact its development by influencing immune responses, affecting the functions of endothelial and vascular smooth muscle cells, and modifying lipid metabolism. Through the analysis of the GEO dataset (GSE42148), we identified differentially expressed genes (DEGs) and lncRNAs (DELs) in CAD patients. We performed functional enrichment and pathway analyses to clarify the roles of these DEGs. To investigate the interactions between DEGs and DELs, we created the lncRNA-mRNA interaction network. To investigate the interactions between DEGs and DELs, we constructed an lncRNAāmRNA interaction network. Candidate lncRNAs were validated by real-time PCR using peripheral blood from CAD patients. Our in vitro study confirmed that LINC00963 and SNHG15 were upregulated in CAD patients compared to the control group. Notably, LINC00963 levels were significantly elevated in patients with a positive family history, hyperlipidemia, hypertension, and diabetes, while SNHG15 expression was higher in smokers. Additionally, a significant negative correlation was found between the expressions of LINC00963 and SNHG15 and the age of the individuals. ROC curve analysis indicated that both lncRNAs have high sensitivity and specificity as biomarkers. Furthermore, this study suggests that LINC00963 and SNHG15 could serve as valuable markers for the early detection of CAD, particularly in younger individuals. It is proposed that these lncRNAs are associated with inflammatory conditions in CAD. Overall, LINC00963 and SNHG15 may act as promising early detection markers for CAD based on bioinformatics and peripheral blood-based validation.
- 1 July 2025
- Published byĀ Springer NatureĀ inĀ Scientific Reports
- Vol.Ā 15 Ā (1) , 1-12
Open AccessIntegrative in Silico and in vitro validation suggest LINC00963 and SNHG15 as candidate biomarkers for coronary artery disease
Despite notable advancements in prevention, medication, and treatment approaches, coronary artery disease (CAD) remains a significant challenge for healthcare systems and the economy. In relation to CAD, long non-coding RNAs (lncRNAs) can impact its development by influencing immune responses, affecting the functions of endothelial and vascular smooth muscle cells, and modifying lipid metabolism. Through the analysis of the GEO dataset (GSE42148), we identified differentially expressed genes (DEGs) and lncRNAs (DELs) in CAD patients. We performed functional enrichment and pathway analyses to clarify the roles of these DEGs. To investigate the interactions between DEGs and DELs, we created the lncRNA-mRNA interaction network. To investigate the interactions between DEGs and DELs, we constructed an lncRNAāmRNA interaction network. Candidate lncRNAs were validated by real-time PCR using peripheral blood from CAD patients. Our in vitro study confirmed that LINC00963 and SNHG15 were upregulated in CAD patients compared to the control group. Notably, LINC00963 levels were significantly elevated in patients with a positive family history, hyperlipidemia, hypertension, and diabetes, while SNHG15 expression was higher in smokers. Additionally, a significant negative correlation was found between the expressions of LINC00963 and SNHG15 and the age of the individuals. ROC curve analysis indicated that both lncRNAs have high sensitivity and specificity as biomarkers. Furthermore, this study suggests that LINC00963 and SNHG15 could serve as valuable markers for the early detection of CAD, particularly in younger individuals. It is proposed that these lncRNAs are associated with inflammatory conditions in CAD. Overall, LINC00963 and SNHG15 may act as promising early detection markers for CAD based on bioinformatics and peripheral blood-based validation.
- 28 May 2025
- Published byĀ Springer NatureĀ inĀ Molecular Biology Reports
- Vol.Ā 52 Ā (1) , 1-14
An overview on cardiac regeneration revolution: exploring the promise of stem cell therapies
Cardiovascular diseases (CVDs) remain the leading cause of global mortality, with myocardial infarction (MI) and subsequent heart failure (HF) posing significant clinical challenges. Despite advancements in pharmacological and surgical interventions, the limited regenerative capacity of the adult human heart necessitates innovative therapeutic strategies. Stem cell-based therapies have emerged as a promising approach to cardiac regeneration, aiming to restore damaged myocardial tissue through cell replacement and paracrine-mediated repair mechanisms. This review provides a comprehensive overview of the current landscape of stem cell therapies for cardiac regeneration, focusing on the molecular mechanisms, cell types, delivery techniques, and recent clinical advancements. We highlight the roles of key signaling pathways, including NOTCH, PI3K/Akt, Wnt/β-catenin, Hippo/YAP, and MAPK, in regulating cardiomyocyte proliferation, angiogenesis, fibrosis, and inflammation. Additionally, we discuss the therapeutic potential of various stem cell types, such as mesenchymal stem cells (MSCs), cardiac progenitor cells (CPCs), induced pluripotent stem cells (iPSCs), and embryonic stem cells (ESCs), in promoting cardiac repair. Despite promising preclinical results, challenges such as low cell retention, immune rejection, and inconsistent clinical outcomes persist. Recent advancements in genetic engineering, and innovative delivery methods, including transendocardial and intracoronary injections, offer new avenues for enhancing therapeutic efficacy. This review underscores the need for further research to optimize stem cell-based therapies, improve clinical trial design, and translate these innovative approaches into effective treatments for heart disease. By addressing these challenges, stem cell therapy holds the potential to revolutionize cardiac regeneration and improve outcomes for patients with ischemic heart disease and heart failure.
- 28 May 2025
- Published byĀ Springer NatureĀ inĀ Molecular Biology Reports
- Vol.Ā 52 Ā (1) , 1-14
An overview on cardiac regeneration revolution: exploring the promise of stem cell therapies
Cardiovascular diseases (CVDs) remain the leading cause of global mortality, with myocardial infarction (MI) and subsequent heart failure (HF) posing significant clinical challenges. Despite advancements in pharmacological and surgical interventions, the limited regenerative capacity of the adult human heart necessitates innovative therapeutic strategies. Stem cell-based therapies have emerged as a promising approach to cardiac regeneration, aiming to restore damaged myocardial tissue through cell replacement and paracrine-mediated repair mechanisms. This review provides a comprehensive overview of the current landscape of stem cell therapies for cardiac regeneration, focusing on the molecular mechanisms, cell types, delivery techniques, and recent clinical advancements. We highlight the roles of key signaling pathways, including NOTCH, PI3K/Akt, Wnt/β-catenin, Hippo/YAP, and MAPK, in regulating cardiomyocyte proliferation, angiogenesis, fibrosis, and inflammation. Additionally, we discuss the therapeutic potential of various stem cell types, such as mesenchymal stem cells (MSCs), cardiac progenitor cells (CPCs), induced pluripotent stem cells (iPSCs), and embryonic stem cells (ESCs), in promoting cardiac repair. Despite promising preclinical results, challenges such as low cell retention, immune rejection, and inconsistent clinical outcomes persist. Recent advancements in genetic engineering, and innovative delivery methods, including transendocardial and intracoronary injections, offer new avenues for enhancing therapeutic efficacy. This review underscores the need for further research to optimize stem cell-based therapies, improve clinical trial design, and translate these innovative approaches into effective treatments for heart disease. By addressing these challenges, stem cell therapy holds the potential to revolutionize cardiac regeneration and improve outcomes for patients with ischemic heart disease and heart failure.
- Open Access
- 6 March 2025
- Published byĀ ElsevierĀ inĀ Biochemistry and Biophysics Reports
- Vol.Ā 42, 101970
Exploring the role of exosomal and non-exosomal non-coding RNAs in Kawasaki disease: Implications for diagnosis and therapeutic strategies against coronary artery aneurysms
- 6 March 2025
- Published byĀ ElsevierĀ inĀ Biochemistry and Biophysics Reports
- Vol.Ā 42, 101970
Open AccessExploring the role of exosomal and non-exosomal non-coding RNAs in Kawasaki disease: Implications for diagnosis and therapeutic strategies against coronary artery aneurysms
- 1 January 2025
- Published byĀ Bentham Science Publishers Ltd.Ā inĀ Current Cardiology Reviews
- Vol.Ā 21 Ā (1) , 1-12
The Relationship between Using Renin-Angiotensin System Inhibitors with Mortality of Atrial Fibrillation: A Systematic Review and Meta-Analysis
Background: Atrial fibrillation (AFib) is a highly prevalent cardiac arrhythmia associated with increased mortality in affected persons. Renin-angiotensin system inhibitors (RASIs) have been suggested as potential therapeutic agents for cardiovascular and renal diseases. Objectives: However, the relationship between RASIs and mortality in AFib patients remains uncertain. Therefore, the present study was designed and implemented for this purpose. Methods: We searched PubMed/MEDLINE, Embase, Web of Science (WOS), Cochrane Library, and Scopus databases for studies published until 12 February 2024 with relevant keywords. We included studies that reported mortality outcomes in AFib patients treated with RASIs and non-users. The data extraction and quality assessment processes were conducted, and subgroup analyses and sensitivity analyses were done. The data were analyzed by Stata 15 using statistical tests, such as Chi-square and I2 tests. Results: A total of 15 studies (2007-2024; n=2,178,565 patients) examined the association between RASI drugs and mortality of patients with AFib. The results indicated that compared to the control group, the odds of AFib mortality in the group receiving RASIs were equal to 0.81(95% CI: 0.71-0.92; P-value ā¤0.001). The study results did not indicate publication bias (Pvalue= 0.733). During the meta-regression analysis, none of the study variables demonstrated a significant relationship with the observed heterogeneity (P-value > 0.20). Cumulative OR results showed that from 2022 onwards, there was enough evidence to confirm the relationship using RASIs with mortality of patients with AFib. Conclusion: Therefore, this meta-analysis suggests that the use of RASI drugs is associated with reduced AFib mortality. However, the authors emphasize the need for further high-quality studies and large-scale randomized clinical trials to validate these findings.
- 1 January 2025
- Published byĀ Bentham Science Publishers Ltd.Ā inĀ Current Cardiology Reviews
- Vol.Ā 21 Ā (1) , 1-12
The Relationship between Using Renin-Angiotensin System Inhibitors with Mortality of Atrial Fibrillation: A Systematic Review and Meta-Analysis
Background: Atrial fibrillation (AFib) is a highly prevalent cardiac arrhythmia associated with increased mortality in affected persons. Renin-angiotensin system inhibitors (RASIs) have been suggested as potential therapeutic agents for cardiovascular and renal diseases. Objectives: However, the relationship between RASIs and mortality in AFib patients remains uncertain. Therefore, the present study was designed and implemented for this purpose. Methods: We searched PubMed/MEDLINE, Embase, Web of Science (WOS), Cochrane Library, and Scopus databases for studies published until 12 February 2024 with relevant keywords. We included studies that reported mortality outcomes in AFib patients treated with RASIs and non-users. The data extraction and quality assessment processes were conducted, and subgroup analyses and sensitivity analyses were done. The data were analyzed by Stata 15 using statistical tests, such as Chi-square and I2 tests. Results: A total of 15 studies (2007-2024; n=2,178,565 patients) examined the association between RASI drugs and mortality of patients with AFib. The results indicated that compared to the control group, the odds of AFib mortality in the group receiving RASIs were equal to 0.81(95% CI: 0.71-0.92; P-value ā¤0.001). The study results did not indicate publication bias (Pvalue= 0.733). During the meta-regression analysis, none of the study variables demonstrated a significant relationship with the observed heterogeneity (P-value > 0.20). Cumulative OR results showed that from 2022 onwards, there was enough evidence to confirm the relationship using RASIs with mortality of patients with AFib. Conclusion: Therefore, this meta-analysis suggests that the use of RASI drugs is associated with reduced AFib mortality. However, the authors emphasize the need for further high-quality studies and large-scale randomized clinical trials to validate these findings.
- Open Access
- 28 December 2024
- Published byĀ Maad Rayan Publishing CompanyĀ inĀ Journal of Nephropharmacology
- Vol.Ā 14 Ā (1) , e12755
Relationship between systemic immune-inflammation Index and contrast-induced acute kidney injury in cardiovascular patients: systematic review and meta-analysis
Introduction: Contrast-induced acute kidney injury (CI-AKI) imposes high costs and various complications on individuals and society. Considering that inflammation is a significant risk factor for CI-AKI incidence, the present research aimed to investigate the relationship between the systematic immune-inflammation (SII) index and the CI-AKI risk in cardiovascular patients using the systematic review and meta-analysis method. Materials and Methods: In the present study, ProQuest, PubMed, Embase, Web of Science, Cochrane, Scopus, and Google Scholar databases were used to search for articles published until October 16, 2024. Data analysis was conducted using the STATA 14 software, and tests with P values < 0.05 were considered statistically significant. Results: There was no significant association between the SII index and risk of CI-AKI in patients who underwent carotid artery angiography (OR: 1; 95% CI: 1, 1.01) or coronary angiography (OR: 1.96; 95% CI: 0.94, 4.11). However, in patients undergoing percutaneous coronary intervention (PCI) (OR: 1.01; 95% CI: 1, 1.02), high SII index levels increased the risk of CI-AKI. High SII index levels (OR: 1.01; 95% CI: 1.01, 1.02), higher ages (OR: 1.04; 95% CI: 1.02, 1.06), high-sensitivity C-reactive protein (hs-CRP) (OR: 1.01; 95% CI: 1, 1.02), hypertension (OR: 1.63; 95% CI: 1.31, 2.03), diabetes mellitus (OR: 1.73; 95% CI: 1.12, 2.68), neutrophil to lymphocyte ratio (NLR) (OR: 1.09; 95% CI: 1.01, 1.17), and neutrophil count (OR: 1.12; 95% CI: 1.08, 1.16) increased the risk of CI-AKI in cardiovascular patients. On the other hand, estimated glomerular filtration rate (eGFR) (OR: 0.98; 95% CI: 0.98, 0.99), lymphocyte count (OR: 0.47; 95% CI: 0.31, 0.71), and hemoglobin (OR: 0.97; 95% CI: 0.96, 0.98), albumin (OR: 0.96; 95% CI: 0.93, 0.99) in individuals with CIN were lower than those in the no-CIN group. Conclusion: High systemic immune-inflammation index levels, age, NLR, hs-CRP, hypertension, diabetes mellitus, and neutrophil count were among the risk factors of CI-AKI incidence in cardiovascular patients. Registration: This study has been compiled based on the PRISMA checklist, and its protocol was registered on the PROSPERO (ID: CRD42024604243) and Research Registry (UIN: reviewregistry1904) website.
- 28 December 2024
- Published byĀ Maad Rayan Publishing CompanyĀ inĀ Journal of Nephropharmacology
- Vol.Ā 14 Ā (1) , e12755
Open AccessRelationship between systemic immune-inflammation Index and contrast-induced acute kidney injury in cardiovascular patients: systematic review and meta-analysis
Introduction: Contrast-induced acute kidney injury (CI-AKI) imposes high costs and various complications on individuals and society. Considering that inflammation is a significant risk factor for CI-AKI incidence, the present research aimed to investigate the relationship between the systematic immune-inflammation (SII) index and the CI-AKI risk in cardiovascular patients using the systematic review and meta-analysis method. Materials and Methods: In the present study, ProQuest, PubMed, Embase, Web of Science, Cochrane, Scopus, and Google Scholar databases were used to search for articles published until October 16, 2024. Data analysis was conducted using the STATA 14 software, and tests with P values < 0.05 were considered statistically significant. Results: There was no significant association between the SII index and risk of CI-AKI in patients who underwent carotid artery angiography (OR: 1; 95% CI: 1, 1.01) or coronary angiography (OR: 1.96; 95% CI: 0.94, 4.11). However, in patients undergoing percutaneous coronary intervention (PCI) (OR: 1.01; 95% CI: 1, 1.02), high SII index levels increased the risk of CI-AKI. High SII index levels (OR: 1.01; 95% CI: 1.01, 1.02), higher ages (OR: 1.04; 95% CI: 1.02, 1.06), high-sensitivity C-reactive protein (hs-CRP) (OR: 1.01; 95% CI: 1, 1.02), hypertension (OR: 1.63; 95% CI: 1.31, 2.03), diabetes mellitus (OR: 1.73; 95% CI: 1.12, 2.68), neutrophil to lymphocyte ratio (NLR) (OR: 1.09; 95% CI: 1.01, 1.17), and neutrophil count (OR: 1.12; 95% CI: 1.08, 1.16) increased the risk of CI-AKI in cardiovascular patients. On the other hand, estimated glomerular filtration rate (eGFR) (OR: 0.98; 95% CI: 0.98, 0.99), lymphocyte count (OR: 0.47; 95% CI: 0.31, 0.71), and hemoglobin (OR: 0.97; 95% CI: 0.96, 0.98), albumin (OR: 0.96; 95% CI: 0.93, 0.99) in individuals with CIN were lower than those in the no-CIN group. Conclusion: High systemic immune-inflammation index levels, age, NLR, hs-CRP, hypertension, diabetes mellitus, and neutrophil count were among the risk factors of CI-AKI incidence in cardiovascular patients. Registration: This study has been compiled based on the PRISMA checklist, and its protocol was registered on the PROSPERO (ID: CRD42024604243) and Research Registry (UIN: reviewregistry1904) website.
- 13 June 2024
- Published byĀ Bentham Science Publishers Ltd.Ā inĀ Cardiovascular & Hematological Disorders-Drug Targets
- Vol.Ā 24, 1-11
Association Between Gallstone Disease and Risk of Mortality of Cardiovascular Disease and Cancer: A Systematic Review and Meta-Analysis
Background: Gallstone disease (GD) is increasing in the world and has various complications. Objective: This study aims to examine the relationship between GD and the risk of mortality from cardiovascular disease (CVD) and cancer using a systematic review and meta-analysis approach. Methods: A comprehensive and systematic search was done in various databases, such as Web of Science (WOS), Scopus, MEDLINE/PubMed, Cochrane, and Embase. The search included studies published from 1980 to December 2023. Heterogeneity was assessed using Chi-square, I2, and forest plots, while publication bias was evaluated through Begg's and Egger's tests. All analyses were performed using Stata 15, with statistical significance set at p <0.05. Results: A pooled analysis of five studies involving 161,671 participants demonstrated that individuals with GD had a significantly higher risk of mortality from CVD (RR 1.29, 95% CI: 1.11-1.50, p <0.001). Importantly, no evidence of publication bias was found based on the results of Begg's test (p =0.806) and Egger's test (p =0.138). Furthermore, the pooled analysis of seven studies, encompassing a total of 562,625 participants, indicated an increased risk of cancer mortality among individuals with GD (RR 1.45, 95% CI: 1.16-1.82, p <0.001). Similarly, no publication bias was detected through Begg's test (p =0.133) and Egger's test (p =0.089). Conclusion: In this study, the evidence of a significant association between GD and an elevated risk of mortality from CVD and cancer is provided. These findings suggest that implementing targeted interventions for individuals with gallstone disease could reduce mortality rates among these patients.
- 13 June 2024
- Published byĀ Bentham Science Publishers Ltd.Ā inĀ Cardiovascular & Hematological Disorders-Drug Targets
- Vol.Ā 24, 1-11
Association Between Gallstone Disease and Risk of Mortality of Cardiovascular Disease and Cancer: A Systematic Review and Meta-Analysis
Background: Gallstone disease (GD) is increasing in the world and has various complications. Objective: This study aims to examine the relationship between GD and the risk of mortality from cardiovascular disease (CVD) and cancer using a systematic review and meta-analysis approach. Methods: A comprehensive and systematic search was done in various databases, such as Web of Science (WOS), Scopus, MEDLINE/PubMed, Cochrane, and Embase. The search included studies published from 1980 to December 2023. Heterogeneity was assessed using Chi-square, I2, and forest plots, while publication bias was evaluated through Begg's and Egger's tests. All analyses were performed using Stata 15, with statistical significance set at p <0.05. Results: A pooled analysis of five studies involving 161,671 participants demonstrated that individuals with GD had a significantly higher risk of mortality from CVD (RR 1.29, 95% CI: 1.11-1.50, p <0.001). Importantly, no evidence of publication bias was found based on the results of Begg's test (p =0.806) and Egger's test (p =0.138). Furthermore, the pooled analysis of seven studies, encompassing a total of 562,625 participants, indicated an increased risk of cancer mortality among individuals with GD (RR 1.45, 95% CI: 1.16-1.82, p <0.001). Similarly, no publication bias was detected through Begg's test (p =0.133) and Egger's test (p =0.089). Conclusion: In this study, the evidence of a significant association between GD and an elevated risk of mortality from CVD and cancer is provided. These findings suggest that implementing targeted interventions for individuals with gallstone disease could reduce mortality rates among these patients.
- Open Access
- 8 June 2024
- Published byĀ Springer NatureĀ inĀ BMC Cardiovascular Disorders
- Vol.Ā 24 Ā (1) , 1
Correction: Inflammatory biomarkers in cardiac syndrome X: a systematic review and meta-analysis
- 8 June 2024
- Published byĀ Springer NatureĀ inĀ BMC Cardiovascular Disorders
- Vol.Ā 24 Ā (1) , 1
Open AccessCorrection: Inflammatory biomarkers in cardiac syndrome X: a systematic review and meta-analysis